Literature DB >> 15279903

Galectin-3 expression in non-small cell lung carcinoma.

Fabio Puglisi1, Alessandro Marco Minisini, Fabio Barbone, Donatella Intersimone, Giuseppe Aprile, Cinzia Puppin, Giuseppe Damante, Igor Paron, Gianluca Tell, Andrea Piga, Carla Di Loreto.   

Abstract

Galectins are a family of animal beta-galactoside-binding lectins involved in malignant transformation and progression. The present study evaluated the immunohistochemical expression of galectin-3 in a consecutive series of 81 radically resected non-small cell lung carcinomas (NSCLCs). The main pattern of galectin-3 expression was cytoplasmic (median percentage of cells with cytoplasmic positivity: 80.0%). The median percentage of tumor cells with nuclear and cytoplasmic co-expression of galectin-3 was 3.5%. No cases with exclusive nuclear immunostaining were observed. Functional interaction between galectin-3 and the thyroid transcription factor-1 (TTF-1) was previously demonstrated by cotransfection experiments. In the present study, concomitant expression of nuclear galectin-3 and TTF-1 was independently associated with a worse clinical outcome (HR 2.0; P = 0.01).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15279903     DOI: 10.1016/j.canlet.2004.03.006

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  16 in total

Review 1.  Galectin-3 and cancer stemness.

Authors:  Pratima Nangia-Makker; Victor Hogan; Avraham Raz
Journal:  Glycobiology       Date:  2018-04-01       Impact factor: 4.313

Review 2.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

3.  Predictive importance of galectin-3 for recurrence of non-small cell lung cancer.

Authors:  Yoko Kataoka; Tomoyuki Igarashi; Yasuhiko Ohshio; Takuya Fujita; Jun Hanaoka
Journal:  Gen Thorac Cardiovasc Surg       Date:  2019-03-22

Review 4.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

Review 5.  Dynamics of galectin-3 in the nucleus and cytoplasm.

Authors:  Kevin C Haudek; Kimberly J Spronk; Patricia G Voss; Ronald J Patterson; John L Wang; Eric J Arnoys
Journal:  Biochim Biophys Acta       Date:  2009-07-16

6.  Galectin-3 overexpression in invasive laryngeal carcinoma, assessed by computer-assisted analysis.

Authors:  Fabiana Alves Miranda; Marcela K Hassumi; Marcia C M Guimarães; Renata T Simões; Tarsia G A Silva; Régia C P Lira; Ana M Rocha; Celso T Mendes; Eduardo A Donadi; Christiane P Soares; Edson G Soares
Journal:  J Histochem Cytochem       Date:  2009-03-30       Impact factor: 2.479

7.  Galectins as cancer biomarkers.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Avraham Raz
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

8.  Galectin-3 and cyclin D1 expression in non-small cell lung cancer.

Authors:  Monika Kosacka; Paweł Piesiak; Aneta Kowal; Marcin Gołecki; Renata Jankowska
Journal:  J Exp Clin Cancer Res       Date:  2011-10-24

9.  Prognostic significance of galectin-3 expression in patients with resected NSCLC treated with platinum-based adjuvant chemotherapy.

Authors:  Seiichiro Kusuhara; Satoshi Igawa; Masaaki Ichinoe; Ryo Nagashio; Yuki Kuchitsu; Yasuhiro Hiyoshi; Kazu Shiomi; Yoshiki Murakumo; Makoto Saegusa; Yukitoshi Satoh; Yuichi Sato; Katsuhiko Naoki
Journal:  Thorac Cancer       Date:  2021-04-01       Impact factor: 3.500

10.  Low expression of Bax predicts poor prognosis in resected non-small cell lung cancer patients with non-squamous histology.

Authors:  Seong Hyun Jeong; Hyun-Woo Lee; Jae Ho Han; Seok Yun Kang; Jin-Hyuk Choi; Youn Mu Jung; Ho Choi; Young Taek Oh; Kwang Joo Park; Sung Chul Hwang; Seung Soo Sheen; Yoon Jung Oh; Jang Hee Kim; Ho-Yeong Lim
Journal:  Jpn J Clin Oncol       Date:  2008-09-04       Impact factor: 3.019

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.